AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, Chief Development Officer, explain the development program, the choice of bronchiectasis and the upcoming Phase 1b/2a trial.
Osivax misses Phase 2b flu vaccine endpoint, shifts focus to combinations
Latest NewsFrench-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, which achieved a nonsignificant efficacy estimate of 24% against a predefined target of 50%. The company is now emphasizing a strategy to combine its candidate with existing seasonal flu vaccines.
Evotec fills CSO vacancy; Sibylla and AL-S Pharma name new CEOs
Latest NewsEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: a swift scientific leadership change at Evotec, a broader reshuffle at Sibylla and a new CEO to guide AL-S Pharma toward Phase 3.
Microbiotica raises £36M to test gut-bacteria capsule in ulcerative colitis
Latest NewsU.K. microbiome company Microbiotica has raised £36 million (€43 million), the first close of a Series C round led by the British Business Bank, to take its ulcerative colitis drug MB310 into Phase 2.
Lakefront offloads CAR-T programs to Armed Cell as Mankind Pharma takes control of the Belgian startup
Latest NewsLakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell Therapeutics for €8 million upfront, while India’s Mankind Pharma has agreed to acquire 70% of the buyer for €48 million.
OMass raises $310M in Europe’s second-largest biotech round of 2026
Latest NewsOxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule pipeline in endocrinology and immunology, including a potential treatment for congenital adrenal hyperplasia that will compete with drugs developed by Vertex and Neurocrine Biosciences.
BioNTech’s mRNA cancer vaccine misses Phase 2/3 endpoint
Latest NewsBioNTech’s BNT113, combined with Keytruda, failed to significantly improve progression-free survival in a Phase 2/3 head and neck cancer trial. The study will continue to assess whether the combination helps patients live longer.
Zealand taps Generate’s AI discovery engine in $1.2B obesity deal
Latest NewsZealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and other metabolic diseases, broadening its pipeline beyond peptides and small molecules.
AATec is pioneering a new approach to lung diseases
slider, Sponsored PublicationsAATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, Chief Development Officer, explain the development program, the choice of bronchiectasis and the upcoming Phase 1b/2a trial.
Lundbeck starts Phase 2; Rewind secures funding; Beactica picks a degrader
Latest NewsBeyond the main headlines, European biotech kept moving this week. Lundbeck and Neurosterix advanced neurological drug programs, Rewind secured funding for myelin repair, and Beactica selected a cancer degrader. Plus, new findings from iOnctura and Coave. Here’s your weekly catch-up.
Undecimal raises $18M to take siRNA beyond the liver
Latest NewsUndecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene-silencing medicines beyond the liver, initially targeting kidney and vascular tissues.